Skip to main content

Health condition · Clinically reviewed

Nerve sheath tumours, from benign schwannoma to a suspected sarcoma pathway.

Most lumps arising from the tissue around a nerve are benign and slow-growing. A minority are malignant - knowing the difference in features matters.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Clinically reviewed

    Written by our editorial team and reviewed by a registered UK clinician before publication.

  • 02

    Sourced from guidance

    Checked against NICE NG161 and peer-reviewed sarcoma literature you can see at the end.

  • 03

    Current for 2026

    Reflects modern UK pathways for suspected sarcoma, including specialist MDT referral routes.

Key facts

Nerve sheath tumours at a glance.

The essentials, in plain English - what they are, why most are harmless, and how the minority that aren’t are found.

  • What it is

    Tumours arising from Schwann cells, perineural cells or fibroblasts that surround peripheral nerves.

  • Most are benign

    Schwannomas and neurofibromas make up the majority - slow-growing and often asymptomatic.

  • A minority are malignant

    Malignant peripheral nerve sheath tumours (MPNST) are rare but carry a high recurrence risk.

  • NF1 link

    Neurofibromatosis type 1 sharply raises lifetime MPNST risk - see our neurofibromatosis type 1 guide.

  • First-line imaging

    MRI characterises the lesion and plans biopsy - the standard first step under NICE NG161.

  • Specialist pathway

    Suspected malignant lesions go to a commissioned sarcoma centre with neurosurgery and genetics input.

Why this guide matters

Telling benign from malignant, early.

Nerve sheath tumours span a wide range from a harmless lump to a rare but serious sarcoma. The three points below shape everything else on this page.

  • Most lesions are entirely benign

    Schwannomas and solitary neurofibromas rarely need anything more than excision if symptomatic, or simple observation.

  • A change in behaviour is the signal

    Pain appearing in a painless lump, or rapid growth, is what separates routine follow-up from urgent sarcoma referral.

  • NF1 changes the risk calculation

    People with neurofibromatosis type 1 carry a lifetime MPNST risk that justifies regular specialist surveillance.

How the diagnosis is made

From first lump to a clear plan.

The steps a UK clinician will normally follow under NICE NG161, in order - so you know what to expect and why.

  1. 01

    Assessing

    History and examination

    A palpable lump along a nerve’s course, its growth rate, pain, and any numbness, tingling or weakness in that nerve’s distribution.

  2. 02

    Assessing

    Tinel’s sign

    Tapping over the lesion reproduces tingling along the nerve - a simple bedside clue that the lump is nerve-related.

  3. 03

    Assessing

    MRI as first-line imaging

    MRI characterises size, margins and relationship to the nerve, and is used to plan any biopsy under NICE NG161.

  4. 04

    Confirming

    Core needle biopsy

    Performed at a specialist sarcoma centre for lesions with concerning features - rapid growth, pain, large size, or an NF1 background.

  5. 05

    Confirming

    Genetic assessment

    Where neurofibromatosis is suspected, genetic assessment clarifies the underlying diagnosis and future risk.

  6. 06

    Preparing

    Specialist sarcoma MDT

    Suspected malignant lesions are discussed at a commissioned sarcoma centre with neurosurgery and genetics represented.

  7. 07

    Preparing

    Treatment planning

    Benign disease is planned for excision or observation; malignant disease is planned for wide excision, often with radiotherapy.

Typical timeline: a first scan to a specialist plan within a few weeks.

Symptoms

What a nerve sheath tumour actually feels like.

A palpable lump along a nerve, with or without sensory or motor change. And the features that mean it’s time to escalate.

  • Palpable lump

    A firm swelling felt along the course of a nerve - the most common first sign, benign or malignant.

  • Pain

    Benign lesions are often painless. New or worsening pain raises concern for malignant change.

  • Rapid growth

    A lump that enlarges quickly over weeks rather than years is a key feature prompting urgent assessment.

  • Numbness or tingling

    Sensory change in the distribution of the affected nerve, from pressure or infiltration of nerve fibres.

  • Weakness

    Motor weakness in muscles supplied by the nerve suggests more significant nerve involvement.

  • Tinel’s sign

    Tingling on tapping over the lesion, radiating along the nerve - a classic clinical sign.

  • Multiple lesions (NF1)

    Numerous neurofibromas across the body point towards neurofibromatosis type 1 rather than a solitary tumour.

  • Red flag - pain with rapid growth

    Pain plus rapid growth plus a new neurological deficit is the combination that should prompt urgent sarcoma referral.

Treatment

How nerve sheath tumours are treated in the UK.

Observation or excision for benign disease, and wide excision plus radiotherapy for malignant disease at a specialist sarcoma centre.

  • Observation

    Small, stable, asymptomatic benign lesions are often simply monitored rather than operated on.

  • Surgical excision (benign)

    Schwannomas and solitary neurofibromas are excised when symptomatic or when diagnosis is uncertain, aiming to preserve nerve function.

  • Wide surgical excision (MPNST)

    Malignant peripheral nerve sheath tumours need wide excision with clear margins at a specialist sarcoma centre.

  • Radiotherapy

    Often given after resection of MPNST given the high risk of local recurrence.

  • Chemotherapy

    Used for advanced or metastatic MPNST, usually as part of a specialist sarcoma protocol.

  • MDT specialist care

    Sarcoma centre, neurosurgery and genetics working together for any suspected malignant nerve sheath tumour.

  • NF1 surveillance

    Regular review for people with neurofibromatosis type 1, given their lifetime MPNST risk.

  • Genetic counselling

    For confirmed or suspected neurofibromatosis, to explain inheritance and plan family screening.

What this guide is based on

The sources behind every claim on this page.

UK national guidance and specialist sarcoma-service standards, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your GP or specialist knows your lump and your history and can tell you which parts apply to you. If in doubt, get seen.

  • NICE. Suspected sarcoma: recognition and referral (NG161).

  • British Orthopaedic Oncology Society. Guidance on soft-tissue and nerve sheath tumours.

  • Royal College of Radiologists. Imaging pathways for suspected sarcoma.

  • NHS England. Specialist commissioned sarcoma services.

Red flags

When a nerve sheath lump needs urgent attention.

Most lumps are benign and can be managed routinely. These are the situations that aren’t - and where a specialist sarcoma opinion is needed.

  • Rapid growth

    A nerve sheath lump enlarging over weeks, not years, is a leading concern for malignant transformation.

  • New pain in a previously painless lump

    Pain developing in a lesion that was previously painless suggests possible malignant change and needs prompt review.

  • Progressive neurological deficit

    New or worsening weakness, numbness or loss of function in the nerve’s distribution warrants urgent specialist assessment.

  • Large size at presentation

    Lesions greater than 5cm carry a higher pre-test probability of sarcoma and should be imaged and referred without delay.

  • NF1 background with a changing lesion

    Any neurofibroma that changes in size, pain or texture in a person with NF1 needs urgent sarcoma-pathway assessment.

  • Deep-seated location

    Lesions deep to the fascia are harder to assess clinically and carry a higher relative risk than superficial ones.

  • Fixed or firm consistency

    A lump that feels fixed to surrounding tissue rather than mobile is a feature that raises suspicion.

  • Recurrence after previous excision

    A lesion returning after prior surgery should be reassessed at a specialist sarcoma centre, not simply re-excised locally.

  • Delayed access to a sarcoma MDT

    Any suspected malignant nerve sheath tumour should reach specialist sarcoma and neurosurgery input without unnecessary delay.

Living with it

A watchful, well-informed approach, not constant worry.

Four things that make the biggest difference day to day - knowing your baseline, reporting change promptly, keeping surveillance if you have NF1, and understanding your genetics.

A quiet reminder

Change, not size alone, is what matters most.

A lump that has looked the same for years is reassuring. It is new pain, new growth or new nerve symptoms that deserve attention.

  1. 01 Monitor

    Know your own baseline

    Note the size, shape and feel of a known lesion so you can recognise genuine change early.

  2. 02 Report

    Flag pain or growth promptly

    New pain, faster growth or new numbness or weakness should be reported rather than watched at home.

  3. 03 NF1 care

    Keep up annual surveillance

    If you have neurofibromatosis type 1, regular specialist review is the main way MPNST is caught early.

  4. 04 Support

    Ask about genetics and family risk

    Genetic assessment can clarify inheritance patterns and guide screening for close relatives.

Frequently asked

Everything we get asked about nerve sheath tumours.

Quick answers on diagnosis, the NF1 link, and how benign and malignant disease are treated.

  • What is a peripheral nerve sheath tumour?

    A tumour arising from the cells that surround a peripheral nerve - Schwann cells, perineural cells or fibroblasts. Most, such as schwannomas and neurofibromas, are benign, but a minority are malignant peripheral nerve sheath tumours (MPNST).

  • How is a nerve sheath tumour diagnosed?

    MRI is used first to characterise the lesion and plan any biopsy. Lesions with concerning features - rapid growth, pain, large size or an NF1 background - go on to core needle biopsy at a specialist sarcoma centre.

  • Are these tumours linked to neurofibromatosis?

    Yes. People with neurofibromatosis type 1 have a markedly increased lifetime risk of MPNST developing within an existing neurofibroma, which is why regular surveillance matters for this group.

  • What symptoms suggest malignant change?

    Pain in a previously painless lump, rapid growth, and new numbness, tingling or weakness in the nerve’s distribution are the features that should prompt urgent specialist assessment.

  • How are benign nerve sheath tumours treated?

    Solitary schwannomas or neurofibromas are excised if they are symptomatic or if the diagnosis is uncertain. Otherwise, stable asymptomatic lesions are simply observed over time.

  • How is a malignant peripheral nerve sheath tumour treated?

    Wide surgical excision at a specialist sarcoma centre is the mainstay, often combined with radiotherapy because of the high recurrence risk. Chemotherapy is used for advanced or metastatic disease, with regular surveillance afterwards.

Related content

Keep reading.

Pulse Healthcare concierge

Send us your enquiry

A concierge service for UK private healthcare. We match you with the best vetted clinics and consultants in our network - they then contact you directly.

So we can match you to the right clinician close to you.

We reply to every enquiry within 24 hours (Mon–Fri). Confidential - your details are never shared outside our vetted consultant network.